ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Consensus PT from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $9.50.

A number of equities research analysts recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, HC Wainwright boosted their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, March 14th.

ProQR Therapeutics Price Performance

PRQR opened at $1.65 on Friday. The company has a market capitalization of $173.60 million, a price-to-earnings ratio of -5.16 and a beta of 0.24. The business’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $2.61. ProQR Therapeutics has a 1 year low of $1.59 and a 1 year high of $4.62.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. lifted its holdings in ProQR Therapeutics by 164.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company’s stock valued at $25,446,000 after purchasing an additional 5,976,813 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $9,426,000. Affinity Asset Advisors LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $7,486,000. Millennium Management LLC grew its position in shares of ProQR Therapeutics by 1,864.4% in the fourth quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company’s stock valued at $7,492,000 after purchasing an additional 2,683,351 shares during the last quarter. Finally, Platinum Investment Management Ltd. bought a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $4,076,000. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).